More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

A Philadelphia cell therapy developer has initiated its first human testing of a potential cancer treatment. Vittoria ...

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell ...

Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphomaVIPER-101 was ...

Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City ...

Applied DNA Sciences (APDN) announced that the State Institute for Drug Control of the Czech Republic approved an application for a Phase I ...

A team of Children's Medical Research Institute (CMRI) scientists has identified a new method for producing a therapeutic ...

Antibody-drug conjugates (ADCs) represent a promising cancer treatment modality designed to deliver highly potent cytotoxic ...

PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. has announced the launch of its Phase 1 clinical trial for VIPER-101, a ...

Deaths from drug overdoses in the US are down – but not overdoses from carfentanil, which have seen a 720% increase.

(MENAFN- EIN Presswire) Porter's five forces analysis illustrates the potency of the buyers and suppliers in the ... "Radio Access Network Market by Communication Infrastructure (Small Cell, Macro ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH ) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G ...